A Phase 3 interventional study of Minocycline hydrochloride capsules and Placebo capsules of Minocycline hydrochloride capsules in Intracerebral Hemorrhage, sponsored by Beijing Tiantan Hospital. Recruiting at 41 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Beijing Tiantan Hospital · Phase 3, Interventional, and Treatment
Among 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital — 14 open to participants now, 15 under way, 3 of them phase 3. Cerebral Hemorrhage · Beijing Tiantan Hospital.
Among the 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 8 of the 14 other live ones, and was the 19th registered.
457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.
Browse Cerebral Hemorrhage studies →14 of the 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Beijing Tiantan Hospital · Sites in China
Beijing Tiantan Hospital · Sites in China
Beijing Tiantan Hospital · Sites in China
Beijing Tiantan Hospital · Sites in China
By country, each count listing its studies:
Of the 112 Cerebral Hemorrhage studies recruiting now, 58 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 1 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 4 · Phase 4 2
First in 2012; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,192 is above the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 240 across the 15 interventional studies, 1,000 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 489 studies on the registry; 293 are open to participants now.
4 of the studies in Cerebral Hemorrhage by Beijing Tiantan Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868511Phase 3Beijing Tiantan HospitalNeuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage | 2027-03-01 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
| NCT07246473Beijing Tiantan HospitalNon-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage | 2027-08-30 |
| NCT07118631Beijing Tiantan HospitalClinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding | 2027-11-30 |
Among the 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.
The aim of this study was to evaluate the efficacy and safety of 5-day Minocycline versus placebo in patients with acute intracerebral hemorrhage within 48 hours of onset. In addition, we will explore the effect of Minocycline versus placebo on indicators of venous neuroinflammation at different time points in patients with acute intracerebral hemorrhage within 48 hours of onset.
A total of 1192 participants will be randomized 1:1 to receive either minocycline or matching placebo for 5 days, in addition to guideline-based standard medical care.
The primary objective is to evaluate the effect of Minocycline in improving the level of 90-day mRS score to 0-3 in patients with acute intracerebral hemorrhage within 48 hours of onset.
The trial is divided into three phases: screening/baseline period, treatment period, and follow-up period. The visit schedule is as follows: Randomized participants are interviewed at screening/baseline period, 72±12 hours, 7±1 days, 90±7 days,180±7 days after randomization, and when events occur.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Minocycline Hydrochloride Capsules (50 mg per capsule). The first dose (200mg, 4 capsules) should be given immediately after randomization (within 30 minutes); Subsequently, 100mg (2 capsules) will be administered once every 12 hours; a total of 10 times (lasting 5 days; the subject with dysphagia will be administrated through a nasal feeding tube).
Drug: Minocycline hydrochloride capsules
Placebo of Minocycline Hydrochloride capsules (50mg per capsule, containing 0 mg of Minocycline). The method of administration was the same as that of treatment group.
Drug: Placebo capsules of Minocycline hydrochloride capsules
50 mg per capsule, containing 50mg of Minocycline Hydrochloride
50 mg per capsule, containing 0 mg of Minocycline Hydrochloride
mRS score 0-3
Modified Rankin Scale score
Time frame: At 90±7 days after randomization
mRS score
Modified Rankin Scale score
Time frame: At 90±7 days and 180±7 days after randomization
Changes in NIHSS score compared with baseline score
NIHSS score
Time frame: At 72±12 hours and 7±1 days after randomization
Changes in Glasgow Coma Scale score compared with baseline score
Glasgow Coma Scale score
Time frame: At 72±12 hours and 7±1 days after randomization
Early neurological deterioration
Early neurological deterioration is defined as a decrease of ≥2 in GCS score or an increase of ≥4 in NIHSS score caused by non-sedatives/sleeping drugs compared with the baseline level.
Time frame: At 72±12 hours and 7±1 days after randomization
Changes in hs-CRP level compared with baseline level
hs-CRP is examined to evaluate the level of systematic inflammation.
Time frame: At 72±12 hours and 7±1 days after randomization
Volume of perihematomal edema (PHE)
Volume of perihematomal edema (PHE) on MRI
Time frame: At 7±1 days after randomization
EQ-5D-5L utility score
Quality of life assessed by the EQ-5D-5L utility score
Time frame: At 90±7 days and 180±7 days after randomization
Recurrent stroke
Recurrent stroke includes ischemic stroke and hemorrhagic stroke.
Time frame: At 90±7 days and 180±7 days after randomization
Combined vascular events
Combined vascular events include stroke, myocardial infarction, and vascular death.
Time frame: At 90±7 days and 180±7 days after randomization
Changes in the levels of venous neuroinflammation indicators compared with baseline levels
Venous neuroinflammation indicators (IL, TNF-α, TGF-β, NFL, etc.)
Time frame: At 72±12 hours and 7±1 days after randomization
Perihematomal blood-brain barrier permeability
Perihematomal blood-brain barrier permeability is assessed using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
Time frame: At 7±1 days after randomization
Hematoma expansion or rebleeding
Hematoma expansion or rebleeding
Time frame: At 72±12 hours and 7±1 days after randomization
Antibiotic-associated diarrhea, enteritis, and constipation
Antibiotic-associated diarrhea, enteritis, and constipation
Time frame: At 7±1 days after randomization
Any bleeding events
Any bleeding events
Time frame: At 90±7 days after randomization
Adverse events (AE)
Adverse events (AE)
Time frame: At 90±7 days after randomization
Serious adverse events (SAE)
Serious adverse events (SAE)
Time frame: At 90±7 days after randomization
Plan to share: Yes
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Minocycline